Novel oral delivery system for subunit vaccine against ETEC
Novel oral delivery system for subunit vaccine against ETEC
批准号:
9770724
负责人:
Martin Klinger
金额:
$22.41万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-08 至 2021-03-31
关键词:
5 year oldAdjuvantAfricaAfrica South of the SaharaAgeAmylasesAnimal ModelAntigensAreaAsiaBacterial InfectionsBindingBiological AssayBrush BorderCause of DeathCellsCessation of lifeChildCommunicable DiseasesCommunitiesCommunity Health AidesDeveloping CountriesDevelopmentDextrinsDiarrheaDigestionDisaccharidesDoseEconomicsEncapsulatedEnteralEnterocytesEnvironmentEnzymesEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsEscherichia coli VaccinesExposure toFamily suidaeFluorescein-5-isothiocyanateFluorescent DyesFormulationGastrointestinal tract structureGlycoside HydrolasesGoalsHIVHealth PersonnelHepatitisHumanImmuneImmune responseImmunizationImmunizeImmunoglobulin AImmunoglobulin GIn VitroIncubatedIntestinesLabelLaboratoriesLatin AmericaLiquid substanceM cellMeasuresMembraneMethodsMicrospheresMilitary PersonnelModelingMucosal Immune SystemMucous MembraneMusNeedlesNewborn InfantOligosaccharidesOralPancreasPancreatic ribonucleasePatientsPepsin APeptide HydrolasesPerformancePhasePopulationPotatoPreventionProteinsPublic HealthQuality of lifeRattusResearch Project GrantsResistanceResourcesSalivaSerumSmall Business Innovation Research GrantSmall IntestinesSouth AmericaStarchStomachStressStructure of aggregated lymphoid follicle of small intestineSubunit VaccinesSurfaceSyringesSystemTestingTimeTrainingTravelTrypsinUniversitiesVaccinesVeterinary Medicineattributable mortalitybasechymotrypsincollegecostdesignexperienceimprovedlow and middle-income countrieslow income countrymouse modelmucosal vaccinenoveloral vaccinepathogenprotein degradationqubitresponsescale upsealsephadexsuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Oral vaccines have the potential to make a revolutionary improvement in the quality of life in
developing countries. Since these vaccines can be administered by community health workers
who are not trained medical personnel, the number of people who can be immunized in a short
period of time is drastically increased while the cost per patient is significantly lowered. Oral
vaccines also avoid the danger of contaminated syringes and needles which is a serious threat in
areas with high rates of HIV and hepatitis. One obstacle to the wider use of oral vaccines against
infectious diseases is that most vaccines are destroyed as they pass through the harsh acidic
environment of the stomach where they are degraded by proteolytic enzymes. The goal of this
research project is to develop a new delivery system for oral vaccines that protects the vaccine
proteins as they pass through the stomach and the lumen of the intestine. This vaccine targets
enterotoxogenic E. coli (ETEC), a major cause of death in young children living in South Asia
and Sub-Saharan Africa. ETEC infections are also the major cause of diarrhea in tourists and
military personnel travelling to the developing world. No vaccine has been licensed for the
prevention of ETEC. This Phase I SBIR research project is designed to shield the ETEC vaccine
proteins within microbeads that remain sealed until they come into direct contact with the wall
of the small intestine. Only then are the encapsulated proteins released from the carriers. As a
result, the vaccine proteins are shielded from destruction by proteases until they are in close
proximity to the M cells of the Peyer’s patches. This should greatly improve the odds that a
vaccine will be taken up by the M cells and be passed on to mucosal immune cells. To establish
proof of concept of this system, we will pursue three specific aims: 1) Optimize the performance
of the microbeads in terms of a) their protection of encapsulated protein antigens from
proteases and b) the release of the antigens upon contact with brush border enzymes; 2) Load
the microbeads with defined amounts of selected ETEC antigens and an established adjuvant;
and 3) Test the ability of the loaded microbeads to induce immune responses in mice when
administered by gavage. An important feature of the delivery system is that it is based on a
natural breakdown product of potato starch. This raises the possibility that the system can be
scaled up at modest cost and that it can provide a feasible option for widespread immunization
in resource-poor communities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金